Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Elaine Tseng"'
Autor:
Yan Weng, Kari R. Fonseca, Yi-an Bi, Sumathy Mathialagan, Keith Riccardi, Elaine Tseng, Andrew J. Bessire, Mathew A. Cerny, David A. Tess, A. David Rodrigues, Amit S. Kalgutkar, John Litchfield, Li Di, Manthena V. S. Varma
Publikováno v:
Drug Metabolism and Disposition. 50:1312-1321
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebf00f47e216d78cc961dc9e84ae92d0
https://doi.org/10.1124/dmd.122.000953
https://doi.org/10.1124/dmd.122.000953
Autor:
Serban Stoica, Chloe Beard, Johanna J M Takkenberg, Mostafa M Mokhles, Mark Turner, John Pepper, Noreen Hopewell-Kelly, Umberto Benedetto, Samer A M Nashef, Ismail El-Hamamsy, Peter Skillington, Mattia Glauber, Ruggero De Paulis, Elaine Tseng, Bart Meuris, Marta Sitges, Victoria Delgado, Markus Krane, Martin Kostolny, Maria Pufulete
Publikováno v:
Heart, 109(11), 857-865. BMJ Publishing Group
ObjectiveThere is uncertainty about surgical procedures for adult patients aged 18–60 years undergoing aortic valve replacement (AVR). Options include conventional AVR (mechanical, mAVR; tissue, tAVR), the pulmonary autograft (Ross) and aortic valv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d6acb13f8c2171ae4739e2ad4688807
https://lirias.kuleuven.be/handle/20.500.12942/719639
https://lirias.kuleuven.be/handle/20.500.12942/719639
Publikováno v:
Biopharmaceutics & Drug Disposition. 39:388-393
PF-06456384 is an extremely potent and selective blocker of the Nav 1.7 sodium channel designed as a potential intravenous (i.v.) analgesic targeting high potency and rapid clearance to minimize the potential for residual effects following the end of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fa23f1b9cf256091442d5e3e4516866
https://doi.org/10.1002/bdd.2156
https://doi.org/10.1002/bdd.2156
Autor:
Jianmin Sun, Thomas Ryckmans, David Fengas, Colin R. Rose, M. Scott Johnson, Matthew Corbett, David James Rawson, Nigel Alan Swain, Joseph S. Warmus, Lyn H. Jones, Brian E. Marron, Aristos J. Alexandrou, David Printzenhoff, C. Elizabeth Payne, Bruce M. Bechle, Rubben Torella, Neil A. Castle, Jonathan W. Theile, Elaine Tseng, David C. Blakemore, Andrew Pike, R. Ian Storer, Neil J. Flanagan, Alan Daniel Brown
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 27:4805-4811
The discovery and selection of a highly potent and selective NaV1.7 inhibitor PF-06456384, designed specifically for intravenous infusion, is disclosed. Extensive in vitro pharmacology and ADME profiling followed by in vivo preclinical PK and efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f22618c2c414697df7e81bc63fdf7005
https://doi.org/10.1016/j.bmcl.2017.09.056
https://doi.org/10.1016/j.bmcl.2017.09.056
Publikováno v:
Biopharmaceuticsdrug disposition. 39(8)
PF-06456384 is an extremely potent and selective blocker of the Na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c29d2c1e8a241d1dbc9e9746dc738141
https://pubmed.ncbi.nlm.nih.gov/30175851
https://pubmed.ncbi.nlm.nih.gov/30175851
Autor:
R Ian, Storer, Andy, Pike, Nigel A, Swain, Aristos J, Alexandrou, Bruce M, Bechle, David C, Blakemore, Alan D, Brown, Neil A, Castle, Matthew S, Corbett, Neil J, Flanagan, David, Fengas, M Scott, Johnson, Lyn H, Jones, Brian E, Marron, C Elizabeth, Payne, David, Printzenhoff, David J, Rawson, Colin R, Rose, Thomas, Ryckmans, Jianmin, Sun, Jonathan W, Theile, Rubben, Torella, Elaine, Tseng, Joseph S, Warmus
Publikováno v:
Bioorganicmedicinal chemistry letters. 27(21)
The discovery and selection of a highly potent and selective Na
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9b1525a17645ac5a672b8a43ff63d92d
https://pubmed.ncbi.nlm.nih.gov/29029933
https://pubmed.ncbi.nlm.nih.gov/29029933
Autor:
Simon, Planken, Douglas C, Behenna, Sajiv K, Nair, Theodore O, Johnson, Asako, Nagata, Chau, Almaden, Simon, Bailey, T Eric, Ballard, Louise, Bernier, Hengmiao, Cheng, Sujin, Cho-Schultz, Deepak, Dalvie, Judith G, Deal, Dac M, Dinh, Martin P, Edwards, Rose Ann, Ferre, Ketan S, Gajiwala, Michelle, Hemkens, Robert S, Kania, John C, Kath, Jean, Matthews, Brion W, Murray, Sherry, Niessen, Suvi T M, Orr, Mason, Pairish, Neal W, Sach, Hong, Shen, Manli, Shi, James, Solowiej, Khanh, Tran, Elaine, Tseng, Paolo, Vicini, Yuli, Wang, Scott L, Weinrich, Ru, Zhou, Michael, Zientek, Longqing, Liu, Yiqin, Luo, Shuibo, Xin, Chengyi, Zhang, Jennifer, Lafontaine
Publikováno v:
Journal of medicinal chemistry. 60(7)
Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial response in EGFR mutant NSCLC patients before resistance me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::424669cfffca599d5b525ea1e0d9fe2e
https://pubmed.ncbi.nlm.nih.gov/28287730
https://pubmed.ncbi.nlm.nih.gov/28287730
Autor:
Patrick Robert Verhoest, Vinod D. Parikh, Carrie Funk, Marielle Delnomdedieu, Wonkyung Byon, Aarti Sawant Basak, Linda S. Wood, Loretta M. Cox, Hongying Gao, Emily Miller, Chang Lin, Elaine Tseng-Lovering, R S Obach
Publikováno v:
Xenobiotica. 44:438-454
1. In early discovery stages, 2-methyl-N-(2'-(pyrrolidinyl-1-ylsulfonyl)-[1,1'-biphenyl]-4-yl)propan-1-amine (PBPA) demonstrated monoamine oxidase A (MAO-A) and cytochrome P450 (CYP)-mediated clearance. While human liver microsomes predicted low CL(b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70b128ee674a78316738ab1a8c083429
https://doi.org/10.3109/00498254.2013.850552
https://doi.org/10.3109/00498254.2013.850552
Autor:
Aarti, Sawant-Basak, Laigao, Chen, Christopher L, Shaffer, Donna, Palumbo, Anne, Schmidt, Elaine, Tseng, Douglas K, Spracklin, Jean-Dominique, Gallezot, David, Labaree, Nabeel, Nabulsi, Yiyun, Huang, Richard E, Carson, Timothy, McCarthy
Publikováno v:
Xenobiotica; the fate of foreign compounds in biological systems. 47(2)
1. Unbound brain drug concentration (C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a7674ae37a695da56c725df6893e3b36
https://pubmed.ncbi.nlm.nih.gov/27353353
https://pubmed.ncbi.nlm.nih.gov/27353353
Autor:
Hengmiao, Cheng, Sajiv K, Nair, Brion W, Murray, Chau, Almaden, Simon, Bailey, Sangita, Baxi, Doug, Behenna, Sujin, Cho-Schultz, Deepak, Dalvie, Dac M, Dinh, Martin P, Edwards, Jun Li, Feng, Rose Ann, Ferre, Ketan S, Gajiwala, Michelle D, Hemkens, Amy, Jackson-Fisher, Mehran, Jalaie, Ted O, Johnson, Robert S, Kania, Susan, Kephart, Jennifer, Lafontaine, Beth, Lunney, Kevin K-C, Liu, Zhengyu, Liu, Jean, Matthews, Asako, Nagata, Sherry, Niessen, Martha A, Ornelas, Suvi T M, Orr, Mason, Pairish, Simon, Planken, Shijian, Ren, Daniel, Richter, Kevin, Ryan, Neal, Sach, Hong, Shen, Tod, Smeal, Jim, Solowiej, Scott, Sutton, Khanh, Tran, Elaine, Tseng, William, Vernier, Marlena, Walls, Shuiwang, Wang, Scott L, Weinrich, Shuibo, Xin, Haiwei, Xu, Min-Jean, Yin, Michael, Zientek, Ru, Zhou, John C, Kath
Publikováno v:
Journal of medicinal chemistry. 59(5)
First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients' disease progresses, often driven by a second-site mutation in the EGFR kinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f69cf3e766e492ce164cc24ad82b59de
https://pubmed.ncbi.nlm.nih.gov/26756222
https://pubmed.ncbi.nlm.nih.gov/26756222